🇺🇸 FDA
Patent

US 10988768

TMPRSS6 iRNA compositions and methods of use thereof

granted A61PA61P25/00A61P25/14

Quick answer

US patent 10988768 (TMPRSS6 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61P, A61P25/00, A61P25/14, A61P25/16, A61P25/18